“Ultivue is now able to offer solutions for a full range of scientific interests, from Discovery, to Translational and into Clinical research fields,” said Michael Natan, CEO of Ultivue. “This recent development opens up a new level of strategic engagement with our customers centered around the identification of complex biomarker signatures and the demonstration of clinical utility of high-plex panels for patient stratification.”
Data generated from this 16-marker assay also showed the co-localization of 5 markers in the same cellular compartment. “This level of specificity on individual cells enables researchers to confidently identify and characterize complex cell phenotypes that would otherwise remain undetected or only partially identified,” added Philippe Mourere, SVP Commercial Operations.
The data highlighting the science behind the 16-plex assay will be one of six posters showcasing the capabilities and applications of the InSituPlex technology on display at the American Association for Cancer Research (AACR) annual meeting. Details ...
